MESA LABORATORIES INC CO
For the period ended Jun 30, 2024. Filed Aug 5, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 5, 2024
MLAB$136.91+7.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
M****esa Laboratories, Inc.**
Condensed Consolidated Statements of Cash Flows
(in thousands)
| Three Months Ended June 30, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities: | ||
| Net income (loss) | $3,388 | $(549) |
| Adjustments to reconcile net income to net cash from operating activities: | ||
| Depreciation of property, plant and equipment | 1,404 | 914 |
| Amortization of acquisition-related intangibles | 4,061 | 7,220 |
| Stock-based compensation expense | 2,928 | 2,968 |
| Gain on extinguishment of convertible notes | (3,197) | - |
| Amortization of step-up in inventory basis | 778 | - |
| Other | 1,409 | 513 |
| Cash from changes in operating assets and liabilities: | ||
| Accounts receivable, net | 3,482 | 6,456 |
| Inventories | (671) | (1,244) |
| Prepaid expenses and other assets | 969 | (2,448) |
| Accounts payable | (388) | (539) |
| Accrued liabilities and taxes payable | (2,811) | (3,217) |
| Unearned revenues | (919) | (135) |
| Net cash provided by operating activities | 10,433 | 9,939 |
| Cash flows from investing activities: | ||
| Purchases of property, plant and equipment | (891) | (270) |
| Net cash (used in) investing activities | (891) | (270) |
| Cash flows from financing activities: | ||
| Proceeds from the issuance of debt, net | 73,465 | - |
| Repayment of debt | (9,438) | (8,000) |
| Repurchase of convertible debt | (71,250) | - |
| Dividends paid | (863) | (859) |
| Other financing, net | (1,023) | (660) |
| Net cash (used in) financing activities | (9,109) | (9,519) |
| Effect of exchange rate changes on cash and cash equivalents | (175) | (684) |
| Net increase (decrease) in cash and cash equivalents | 258 | (534) |
| Cash and cash equivalents at beginning of period | 28,214 | 32,910 |
| Cash and cash equivalents at end of period | $28,472 | $32,376 |
See accompanying notes to Condensed Consolidated Financial Statements.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.